Follicular lymphoma: treatment and prognostic factors

Detalhes bibliográficos
Autor(a) principal: Luminari,Stefano
Data de Publicação: 2012
Outros Autores: Bellei,Monica, Biasoli,Irene, Federico,Massimo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000100015
Resumo: Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.
id ABHHTC-1_fb0c82c94ef148272d2061a64a813ae7
oai_identifier_str oai:scielo:S1516-84842012000100015
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Follicular lymphoma: treatment and prognostic factorsLymphoma, follicular/drug therapyAntineoplastic combined chemotherapy protocols/therapeutic useDoxorubicin/therapeutic useLymphoma, non-HodgkinAntibodies, monoclonalPrognosisFollicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000100015Revista Brasileira de Hematologia e Hemoterapia v.34 n.1 2012reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20120015info:eu-repo/semantics/openAccessLuminari,StefanoBellei,MonicaBiasoli,IreneFederico,Massimoeng2012-03-13T00:00:00Zoai:scielo:S1516-84842012000100015Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2012-03-13T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Follicular lymphoma: treatment and prognostic factors
title Follicular lymphoma: treatment and prognostic factors
spellingShingle Follicular lymphoma: treatment and prognostic factors
Luminari,Stefano
Lymphoma, follicular/drug therapy
Antineoplastic combined chemotherapy protocols/therapeutic use
Doxorubicin/therapeutic use
Lymphoma, non-Hodgkin
Antibodies, monoclonal
Prognosis
title_short Follicular lymphoma: treatment and prognostic factors
title_full Follicular lymphoma: treatment and prognostic factors
title_fullStr Follicular lymphoma: treatment and prognostic factors
title_full_unstemmed Follicular lymphoma: treatment and prognostic factors
title_sort Follicular lymphoma: treatment and prognostic factors
author Luminari,Stefano
author_facet Luminari,Stefano
Bellei,Monica
Biasoli,Irene
Federico,Massimo
author_role author
author2 Bellei,Monica
Biasoli,Irene
Federico,Massimo
author2_role author
author
author
dc.contributor.author.fl_str_mv Luminari,Stefano
Bellei,Monica
Biasoli,Irene
Federico,Massimo
dc.subject.por.fl_str_mv Lymphoma, follicular/drug therapy
Antineoplastic combined chemotherapy protocols/therapeutic use
Doxorubicin/therapeutic use
Lymphoma, non-Hodgkin
Antibodies, monoclonal
Prognosis
topic Lymphoma, follicular/drug therapy
Antineoplastic combined chemotherapy protocols/therapeutic use
Doxorubicin/therapeutic use
Lymphoma, non-Hodgkin
Antibodies, monoclonal
Prognosis
description Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000100015
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000100015
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5581/1516-8484.20120015
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.34 n.1 2012
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213111556997120

Registros relacionados